STUART: Spend more on quality pre-K education
Fundamental to the American experience is the belief that our children have opportunity to reach whatever heights to which they aspire.
Fundamental to the American experience is the belief that our children have opportunity to reach whatever heights to which they aspire.
Vince Caponi will step down as CEO of the St. Vincent Health hospital system July 1 to become senior vice president of St. Louis-based Ascension Health Alliance, the parent organization of St. Vincent. He will also be executive chairman of the board for St. Vincent Health. During a search for Caponi’s permanent replacement, Ian Worden will serve as interim CEO. Worden since 2008 has been chief operating officer of the 22-hospital system, the second-largest in Indiana. Worden previously served as St. Vincent’s chief financial officer for eight years.
The failures raise pressure on Lilly’s experimental diabetes and cancer drugs to make it to market to offset looming patent expirations.
Plaintiffs say the case, which heads to court Thursday, may reduce the $6.4 billion in annual revenue that universities get from athletics by as much as 50 percent.
Ice Miller gave up two floors at the OneAmerica Tower and Bingham Greenebaum Doll one floor at Market Tower as they and other law firms search for ways to cut costs in a highly competitive market.
The attorney charged with recovering some $200 million for the 5,300 investors bilked by Tim Durham’s Fair Finance Co. plans to continue filing lawsuits for reparations into next year.
It looks like Eli Lilly and Co. has a winner. The Indianpaolis-based drugmaker’s experimental diabetes drug dulaglutide helped patients with Type 2 diabetes lose weight while suffering only manageable side effects, according to Phase 3 clinical trial data released over the weekend at the American Diabetes Association meeting in Chicago. According to Bloomberg News, dulaglutide, if approved, may be a significant competitor to Novo Nordisk A/S’ Victoza, which generated $1.64 billion in 2012. A clinical trial comparing the drugs may report results by the end of the year. “We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year. Dulaglutide is projected to sell $835 million in 2018, according to the average of six analysts’ estimates compiled by Bloomberg. Martin said the drug would be the only weekly injection in the class that doesn’t require patients to prepare the dose for administration.
The California Public Employees Retirement System saved $5.5 million, or 19 percent of its affected medical claims, under a two-year pilot project with Indianapolis-based WellPoint Inc. that steered patients away from high-cost health care providers that don’t produce better outcomes. WellPoint executives told Bloomberg News that the cost-capping, or reference-pricing, policy employed in the pilot program is now gaining momentum among employers. The California pension program, known as Calpers, became a partner in the pilot program after a WellPoint analysis found similar hip and knee surgeries cost anywhere from $15,000 to $110,000 per patient, with no difference in patient outcomes, according to Bloomberg. So in 2011, Calpers and WellPoint’s Anthem Blue Cross unit began steering patients toward 46 hospitals that agreed to keep their costs below $30,000—known as the program's “reference price.” If workers went to another provider, then they were responsible for any costs above $30,000. About 400 members opted for the designated hospitals in 2011, a 21-percent increase over previous years. Calpers’ in-patient costs for hip and knee surgeries dropped to an average of $28,695 from $35,400, according to WellPoint. The study was conducted by HealthCore, a research unit owned by WellPoint, and released Sunday at the AcademyHealth Annual Research Meeting in Baltimore.
Researchers at the Indiana University School of Medicine blocked the progression of Type 1 diabetes among newly diagnosed patients using a drug originally sold to treat psoriasis. In a clinical trial involving 49 patients, those who were given the drug alefacept (sold under the brand name Amevive) kept producing the same amount of insulin over the next year, while patients receiving a placebo saw their level of insulin drop over the same period. If the results are repeated in studies involving more patients, the drug could enable Type 1 diabetics to maintain some insulin production and avoid the debilitating complications caused by the disease, said Dr. Mark R. Rigby, a professor of pediatrics at the IU medical school. Nearly 3 million people are estimated to have Type 1 diabetes in the United States. Although the disease can be managed with insulin injections, it cannot be reversed or cured. Long-term complications can include visual impairment, heart disease, stroke, problems in the extremities leading to amputation, and other problems.
An Indiana University School of Medicine researcher has received a $3.8 million three-year grant from the National Institutes of Health to study estrogen as a treatment for schizophrenia using an unreleased drug developed by Eli Lilly and Co. A team led by Dr. Alan Breier, a professor of psychiatry at the IU medical school, will use a drug discovered by Lilly scientists that mimics some of the actions of the hormone estrogen, but without many of the side effects, such as feminization in men and uterine cancer in women. Breier's study is one of nine projects to receive support from a new NIH program called Discovering New Therapeutic Uses for Existing Molecules.
Indianapolis Public Schools has narrowed its search for a superintendent to three out-of-state candidates who have never served as the top leader at a school district before.
Some of the most secret governments are on the local level.
There has been much discussion recently about the need to “beef up” Marion County law enforcement to reduce crime. I agree. The Indianapolis public safety director recently reported that only about half of the sworn officers are on the street.
A good friend has come up with a good idea. I know it is a good idea because, when he presented it to me and another friend, both of us were skeptical. Such is the inevitable fate of good ideas among friends.
Channel 13’s chief meteorologist and 10-time Emmy winner reportedly was offered a pay cut and lesser role to make room for Angela Buchman.
The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases.
Forefront gives you a wide range of opinions in a tidy package.
Congressman Marvin Stutzman is hardly alone in waging what seems like a mean-spirited campaign against the “least of us.”
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
The IPS board has chosen Lewis Ferebee from North Carolina to replace Eugene White, who led IPS for nearly eight years. The 39-year-old Ferebee has been chief of staff in the Durham Public Schools district, roughly the same size as IPS.
The federal government is set to decide this month whether the federal Medicare program should pay for a $3,000 test that for the first time accurately identifies the signature brain plaques of Alzheimer’s disease, according to Bloomberg News. The test, approved last year by U.S. regulators, uses Eli Lilly and Co.’s Amyvid imaging agent to trace the brain protein amyloid. Alzheimer’s disease affects 5 million Americans, a number that patient advocates say could double by 2050. But the test is controversial because there are no available treatments that even slow the progression of Alzheimer’s disease. A final decision from the federal Centers for Medicare & Medicaid Services will come July 9. While a negative decision would limit use of the tests, approval would probably lead to coverage from private health insurers, too.
Nyhart Actuary & Employee Benefits plans to expand its Indianapolis headquarters and create as many as 25 jobs here by 2017. The firm will invest $840,000 to lease and equip an additional 8,000 square feet of office space, according to Nyhart CEO Thomas Toten. Nyhart currently is negotiating an expansion of the 20,000 square feet it leases at 8415 Allison Pointe Blvd. in the Castleton area. Nyhart currently has 68 full-time employees in Indianapolis and about another 30 across five other states. The firm already has started hiring additional actuaries, administrators and benefit consultants from college programs for its Indianapolis expansion. Founded in 1943, Nyhart provides consulting services to more than 1,000 public and private companies in 48 states on issues such as pensions, retirement benefits, compensation and other employee benefits. Nyhart has been in growth mode lately. In August, Nyhart acquired San Diego-based The Epler Co., a regional actuarial, employee benefits and compensation strategies firm.
Lilly Endowment Inc. will give $10 million to help start the Indiana Biosciences Institute. The institute is already due to receive $25 million in startup funds from the state. The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases. The effort has been spearheaded by BioCrossroads, an Indianapolis-based life sciences organization, and has received significant support from Gov. Mike Pence and John Lechleiter, the CEO of Eli Lilly and Co. The institute needs to raise $15 million over the next year or so to fully fund its startup efforts. Beyond that, the institute hopes to raise an endowment of $310 million to help fund its operations. It also hopes its researchers attract steady grants from life sciences research companies, such as Indianapolis-based Lilly and Bloomington-based Cook Group Inc.
Eli Lilly and Co. won a United Kingdom patent lawsuit against a Johnson & Johnson unit over a potential treatment for Alzheimer’s disease, according to Bloomberg News. A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London on June 25. Both companies are developing treatments targeting the buildup of plaque in patients’ brains that’s linked to the condition. Companies developing the first treatments for Alzheimer’s are competing for what might be a $20 billion market, according to a report last year by Deutsche Bank AG analysts.
The head of the state Family and Social Services Administration said the federal government is expected to approve an extension of the Healthy Indiana Plan, but a request to use the plan for an Indiana Medicaid expansion could take much longer. According to the Associated Press, FSSA Secretary Debra Minott said Gov. Mike Pence directed her and others to ensure those already enrolled in HIP are secure before negotiating an expansion through the program. Roughly 40,000 low-income residents are enrolled in the program, which operates under a federal waiver. But the waiver is set to expire at the end of the year, potentially leaving enrollees without coverage. Pence resubmitted an application with the Centers for Medicare and Medicaid Services in April seeking to use the state's hybrid health savings account plan as the vehicle for Medicaid expansion. CMS rejected an earlier request from former Gov. Mitch Daniels, citing concerns about the premium paid by members and a need for improved coverage. The expansion would cover residents earning up to 138 percent of the federal poverty level, using new funds authorized by Obamacare.
A Carmel company that markets a device which plugs into a car’s diagnostic port to monitor the vehicle's performance has filed a patent-infringement lawsuit against a better-known competitor.
Congress should act immediately to reverse increase in interest rate.